Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) have been assigned an average rating of “Moderate Buy” from the six analysts that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, four have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $41.80.

ORKA has been the subject of a number of analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oruka Therapeutics in a research report on Wednesday, October 8th. BTIG Research reissued a “buy” rating and issued a $56.00 target price on shares of Oruka Therapeutics in a research report on Monday, September 29th. Wall Street Zen cut Oruka Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, October 18th. Wedbush reissued an “outperform” rating and issued a $40.00 price objective on shares of Oruka Therapeutics in a report on Tuesday, August 12th. Finally, HC Wainwright reiterated a “buy” rating and set a $45.00 target price on shares of Oruka Therapeutics in a research report on Monday, August 18th.

Oruka Therapeutics Trading Down 2.6%

ORKA stock opened at $26.65 on Thursday. Oruka Therapeutics has a 1-year low of $5.49 and a 1-year high of $30.51. The stock has a market cap of $1.11 billion, a price-to-earnings ratio of -9.48 and a beta of -0.29. The company’s 50 day moving average is $18.37 and its 200 day moving average is $13.93.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings data on Monday, August 11th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.02. As a group, sell-side analysts forecast that Oruka Therapeutics will post -3.41 EPS for the current fiscal year.

Institutional Investors Weigh In On Oruka Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Cannon Global Investment Management LLC bought a new stake in shares of Oruka Therapeutics during the first quarter valued at approximately $195,000. Jefferies Financial Group Inc. raised its stake in shares of Oruka Therapeutics by 15.7% in the first quarter. Jefferies Financial Group Inc. now owns 405,029 shares of the company’s stock worth $4,156,000 after acquiring an additional 55,000 shares during the last quarter. Candriam S.C.A. acquired a new position in shares of Oruka Therapeutics during the first quarter worth approximately $1,197,000. AlphaQuest LLC acquired a new stake in shares of Oruka Therapeutics in the first quarter valued at approximately $168,000. Finally, Affinity Asset Advisors LLC raised its position in Oruka Therapeutics by 47.9% in the 1st quarter. Affinity Asset Advisors LLC now owns 545,362 shares of the company’s stock worth $5,595,000 after purchasing an additional 176,664 shares during the last quarter. Institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.